Skip to content
CJC Ipa Direct A mechanism-first reading of the CJC-1295 and ipamorelin literature — two GH secretagogues, two receptors, and what the studies actually measured.

Where each health claim came from

Which studies back CJC-1295 Ipamorelin claims?

The list separates work on people, animals, and grown cells.

Read what the people tests foundGo back to the main answer

What each study found and where to read it

How can you check a claim? Its number points to the matching paper below.

Each entry gives its authors plus the journal and year. DOI is a lasting web address. PubMed is run by the government and lists medical papers.

In 1990, men got two related drugs and showed a bigger rise in growth hormone. In 2002, grown cells made more of a chemical when both drugs were present. Two CJC-1295 papers from 2006 found higher blood-test levels in people. The second 2006 paper found that natural hormone rises continued. In 2005, rat work showed how the DAC hook made the drug last. In 1998, animal work found higher growth hormone without higher stress hormones. A 2018 paper reviewed harms, including high blood sugar.

Two entries cover the unrelated rat bowel drug TZP-101. They appear because another page explains why rat bowel work can't answer your question. The tesamorelin paper is background on a different drug. None tested CJC-1295 and ipamorelin in one vial.

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
  4. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  8. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. ↗
  9. Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
  10. Ho KY, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968-75. ↗
  11. Fraser GL, et al. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol. 2009;604(1-3):132-7. ↗
  12. Venkova K, et al. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci. 2007;52(9):2241-8. ↗
  13. Halmos G, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. ↗
  14. Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024;266:107550. ↗